Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1372

1.

Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.

Koren MJ, Davidson MH, Wilson DJ, Fayyad RS, Zuckerman A, Reed DP; ALLIANCE Investigators..

Am J Kidney Dis. 2009 May;53(5):741-50. doi: 10.1053/j.ajkd.2008.11.025. Epub 2009 Feb 11.

PMID:
19216014
2.

Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.

Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK; TNT (Treating to New Targets) Investigators..

J Am Coll Cardiol. 2008 Apr 15;51(15):1448-54. doi: 10.1016/j.jacc.2007.11.072.

3.
4.

Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events.

Arca M, Gaspardone A.

Drugs. 2007;67 Suppl 1:29-42. Review.

PMID:
17910519
5.

Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study.

Athyros VG, Elisaf M, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, Milionis HJ, Mikhailidis DP; GREACE Study Collaborative Group..

Am J Kidney Dis. 2004 Apr;43(4):589-99.

PMID:
15042535
6.

Intensive lipid lowering with atorvastatin in patients with stable coronary disease.

LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK; Treating to New Targets (TNT) Investigators..

N Engl J Med. 2005 Apr 7;352(14):1425-35. Epub 2005 Mar 8.

7.

Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.

Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S, Waters D.

Diabetes Care. 2006 Jun;29(6):1220-6.

PMID:
16731999
8.

Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study.

Wenger NK, Lewis SJ, Welty FK, Herrington DM, Bittner V; TNT Steering Committee and Investigators..

Heart. 2008 Apr;94(4):434-9. Epub 2007 Dec 10.

PMID:
18070940
9.

Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).

Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Charlton-Menys V, DeMicco DA, Fuller JH; CARDS Investigators..

Am J Kidney Dis. 2009 Nov;54(5):810-9. doi: 10.1053/j.ajkd.2009.03.022. Epub 2009 Jun 21.

PMID:
19540640
10.

Efficacy of atorvastatin after LDL-cholesterol-based dose selection in high risk dyslipidaemic patients: results of the target dose study.

Ducobu J, Claeys M, Commers K, Van Mieghem W, Nachtergaele H, Vandenbroucke M, Deforce J.

Curr Med Res Opin. 2007 Aug;23(8):1821-7.

PMID:
17609019
12.

Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease.

Wenger NK, Lewis SJ, Herrington DM, Bittner V, Welty FK; Treating to New Targets Study Steering Committee and Investigators..

Ann Intern Med. 2007 Jul 3;147(1):1-9.

PMID:
17606955
13.

Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).

LaRosa JC, Grundy SM, Kastelein JJ, Kostis JB, Greten H; Treating to New Targets (TNT) Steering Committee and Investigators..

Am J Cardiol. 2007 Sep 1;100(5):747-52. Epub 2007 Jun 14.

PMID:
17719314
14.

Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study.

Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK; Treating to New Targets Investigators..

Clin J Am Soc Nephrol. 2007 Nov;2(6):1131-9. Epub 2007 Oct 17.

15.
16.
18.
20.

Impact of high-dose atorvastatin in coronary heart disease patients age 65 to 78 years.

Koren MJ, Feldman T, Mendes RA.

Clin Cardiol. 2009 May;32(5):256-63. doi: 10.1002/clc.20448.

Supplemental Content

Support Center